Vielight PBM Increases Brain Cell Growth

This is the latest publication showing the impact of safe, self-administered infrared light therapy as an effective treatment neurotrauma and related neurodegenerative conditions. The device used in this study was the Vielight Duo which provides both 10hz and 40hz stimulation to the brain as well as the body's blood supply through intranasal stimulation.  The study results suggest that the 8 weeks of stimulation resulted in increased brain volume in an number of regions and a decrease in hippocampal volume and overall network connectivity in relation to the anterior cingulate cortex (ACC). The assumption that the intranasal stimulation would stimulate hippocampal activity is not supported by this study's results as the power density of the intranasal applicator is lower than the transcranial diodes and the amount of photons that could reach the brain would be rather limited. The intranasal unit does provide an excellent vehicle for stimulating the entire body's blood supply as it passes through the facial region every 4 minutes and thereby can irradiate all the free floating mitochondria now found to be in the blood stream. 
                               "Along with other data, the results suggested that the free-floating mitochondria
                               in healthy blood were in fact functioning, respiring organelles. The team estimates
                               that there could be between 200,000 and 3.7 million cell-free, intact mitochondria
                               per milliliter of blood plasma." 
Z.A.A. Dache et al., “Blood contains circulating cell-free respiratory competent mitochondria,” The FASEB Journal, doi:10.1096/fj.201901917RR, 2020. 

Quietmind Fdn. has been a long time advocate of PBM treatment and has taken a leading role in the integration of Vielight and other forms of PBM with neurofeedback and functional medicine. This study further illustrates the need for careful titration of stimulation dosing in order to avoid negative reactions (headaches) which can result from overstimulation. QMF provides consultation to Vielight users to optimize clinical results while minimizing adverse response potential.

The documented lack of improvement in delayed recall after 8 weeks of treatment while free recall did improve suggests the lack of neural connectivity improvement. This is not surprising and has been discussed in previous publications and underscores the relevance for an integrative treatment approach that seeks to improve both tissue level pathology with PBM and neural connectivity using brainwave biofeedback or neurofeedback training. This therapeutic combination leverages the value of increased perfusion, oxygenation and ATP production while renormalizing neural connectivity.  

Quietmind offers clinical and technical consultation to anyone purchasing Vielight devices through our clinical trial programs. Please contact our office for details info@quietmindfdn.org or call 610-940-0488.
.
www.frontiersin.org/articles/10.3389/fneur.2020.00952/full